Where should I publish my paper?
Paste your title, abstract or keywords. The finder matches them to research topics and suggests ranked journals that publish most on those topics.
Journals for “Nanoplatforms for cancer theranostics”
Suggested journals
Topic match is relative to the best match in this search (100% = best). Fees are shown only where DOAJ records them.
| # | Journal | Topic match | ITS Journal Score | Global rank | Papers 2021–2025 | Open access | Fee (APC) |
|---|---|---|---|---|---|---|---|
| 1 | Journal of Nanobiotechnology BioMed Central · United Kingdom · DOAJ | 95% | 90.7 | #205 | 3,204 | 100% | 3,190 EUR |
| 2 | Nano Today Elsevier BV · United Kingdom | 94% | 89.6 | #281 | 1,727 | 16% | Not recorded |
| 3 | Exploration Wiley · China · DOAJ | 93% | 84.7 | #898 | 500 | 100% | US$3,500 |
| 4 | Journal of Nanotheranostics Multidisciplinary Digital Publishing Institute · Switzerland · DOAJ | 100% | 66.3 | #8,993 | 98 | 100% | Not recorded |
| 5 | Cancer Nanotechnology BioMed Central · Austria · DOAJ | 88% | 74.9 | #4,188 | 294 | 100% | 1,790 EUR |
| 6 | Advanced Therapeutics Wiley · Germany | 88% | 72.6 | #5,375 | 912 | 55% | Not recorded |
| 7 | Theranostics Ivyspring International Publisher · Australia · DOAJ | 74% | 92.5 | #118 | 2,343 | 100% | 4,500 AUD |
| 8 | Nanotheranostics Ivyspring International Publisher · Australia · DOAJ | 83% | 72.4 | #5,495 | 167 | 100% | 750 AUD |
| 9 | Materials Today Bio Elsevier BV · United Kingdom · DOAJ | 76% | 82.3 | #1,413 | 2,613 | 100% | US$3,290 |
| 10 | Advanced Healthcare Materials Wiley · Germany | 71% | 88.3 | #407 | 5,631 | 51% | Not recorded |
| 11 | Acta Pharmaceutica Sinica B Elsevier BV · The Netherlands · DOAJ | 69% | 88.0 | #431 | 1,839 | 100% | US$2,600 |
| 12 | Journal of Materials Chemistry B Royal Society of Chemistry · United Kingdom | 66% | 85.5 | #745 | 5,318 | 29% | Not recorded |
| 13 | Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology Wiley · United States | 61% | 83.3 | #1,178 | 412 | 49% | Not recorded |
| 14 | Biomaterials Research BioMed Central · United Kingdom · DOAJ | 60% | 79.4 | #2,358 | 573 | 100% | Not recorded |
| 15 | Aggregate Wiley · United States · DOAJ | 56% | 83.8 | #1,082 | 989 | 100% | 2,600 EUR |
| 16 | BIO Integration Compuscript (Ireland) · Ireland · DOAJ | 64% | 66.5 | #8,897 | 150 | 100% | Not recorded |
| 17 | Biomaterials Science Royal Society of Chemistry · United Kingdom | 54% | 84.2 | #997 | 2,880 | 35% | Not recorded |
| 18 | Advanced Science Wiley · Germany · DOAJ | 49% | 91.7 | #150 | 14,728 | 100% | US$6,730 |
| 19 | ACS Applied Bio Materials American Chemical Society · United States | 54% | 82.5 | #1,363 | 3,408 | 23% | Not recorded |
| 20 | Nanomedicine Nanotechnology Biology and Medicine Elsevier BV · United States | 58% | 73.5 | #4,879 | 522 | 37% | Not recorded |
| 21 | Nanomedicine Future Medicine · United Kingdom | 53% | 81.4 | #1,699 | 996 | 51% | Not recorded |
| 22 | Bioactive Materials Elsevier BV · China · DOAJ | 48% | 88.3 | #410 | 2,211 | 100% | Not recorded |
| 23 | Smart Materials in Medicine Elsevier BV · China · DOAJ | 56% | 70.8 | #6,313 | 185 | 100% | Not recorded |
| 24 | Advanced NanoBiomed Research Wiley · Germany · DOAJ | 56% | 70.4 | #6,574 | 654 | 100% | US$4,030 |
| 25 | Photodiagnosis and Photodynamic Therapy Elsevier BV · The Netherlands · DOAJ | 54% | 73.7 | #4,780 | 3,032 | 57% | US$2,960 |
| 26 | Materials Today Advances Elsevier BV · United Kingdom · DOAJ | 54% | 72.7 | #5,274 | 532 | 100% | US$4,170 |
| 27 | International Journal of Nanomedicine Dove Medical Press · New Zealand · DOAJ | 43% | 89.8 | #265 | 2,971 | 100% | Not recorded |
| 28 | Research American Association for the Advancement of Science · United States · DOAJ | 44% | 84.3 | #983 | 1,437 | 100% | US$2,000 |
| 29 | Asian Journal of Pharmaceutical Sciences Elsevier BV · China · DOAJ | 46% | 78.8 | #2,569 | 284 | 100% | Not recorded |
| 30 | Biomaterials Elsevier BV · United Kingdom | 38% | 93.4 | #83 | 2,871 | 29% | Not recorded |
Before you submit
Use this list as a shortlist, not a decision. For each journal, read its aims and scope and a few recent articles, check its peer-review and fee policy on its own website, and confirm any indexing (Scopus, Web of Science, PubMed) with the indexer itself. Be careful with journals that promise very fast acceptance or that contact you by email asking for papers.
How the ITS Journal Score works
One formula applies to every ranked journal, using open data from OpenAlex: 45% citation impact, 35% h-index and 20% size (papers published 2021–2025). Citation impact is the smaller of the journal's two-year mean citedness and its five-year citations per paper, so a journal whose output collapsed cannot jump to the top on old citations. Each part is half a percentile and half a log-scaled value, so the very top is still separated. Growth and open-access share are shown separately and are not part of the score.
A journal is ranked only if it published at least 50 papers in 2021–2025 and was active in at least five of the last six years. Field rankings compare a journal only with journals in the same field; the field is the OpenAlex field with most of the journal's recent papers, or "Multidisciplinary" when no field has 30% of them.
What this is not: the ITS Journal Score is not a Journal Impact Factor, CiteScore or SJR, and this site does not say whether a journal is indexed in Scopus, Web of Science or PubMed. Always confirm aims and scope, indexing, peer review and fees on the journal's own website before you submit.